TuHURA Biosciences, Inc. HURA Contingent Value Rights Associated With Kintara Merger

Contingent Value Rights Associated With Kintara Merger at other companies

XOMA CorporationXOMA

-$131K-233%

XOMA CorporationXOMA

$7.18M—

XOMA CorporationXOMA

$10.89M—

Pacira BioSciences, Inc.PCRX

$15.79M-10.1%

Core Scientific, Inc.CORZ

-$1.04M-108%

Rigel PharmaceuticalsRIGL

$5M—

Other financials

Income statement

See full

Revenue-—

Net income-$7.5M-13.1%

EPS (diluted)-$0.13+13.3%

Balance sheet

See full

Cash & equivalents$6.3M+1.3%

Total debt$456.9K+178%

Total equity$23.2M+135%

Total assets$29.7M+103%

Cash flow

See full

Operating cash flow-$4.4M+6.9%

CapEx$48.8K+14.5%

Free cash flow-$4.5M+6.7%

Valuation

See full

Market cap$155.39M+45.8%

Enterprise value$149.54M+52.3%

Returns & leverage

See full

Return on equity-187.2%—

Debt / equity0×0.0×

Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept hura:ContingentValueRightsAssociatedWithKintaraMerger.

The official record: TuHURA Biosciences, Inc.’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s contingent value rights associated with kintara merger.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s contingent value rights associated with kintara merger?: TuHURA Biosciences, Inc. (HURA) reported contingent value rights associated with kintara merger of $1.28M in Q4 2024.
What does contingent value rights associated with kintara merger mean?: Represents the estimated value of contractual rights granted to shareholders that provide additional payments if specific future milestones are achieved. These instruments are often used in mergers to bridge valuation gaps between the buyer and seller.